XON Overview
Upcoming Projects (XON)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (XON)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (XON)
-
Ziopharm (ZIOP) estimates completion of Phase 1 study of Autologous CD19-specific T Cells Infusion in patients with Lymphoma in late 2018
Tickers: ZIOP, XON
Occurred on: Aug 08, 2019 -
Ziopharm (ZIOP) to complete Phase 1 trial of Allogeneic CD19-Specific T Cells From Peripheral Blood in HSCT patients by December 2016 - On Hold
Tickers: ZIOP, XON
Occurred on: Jun 18, 2018 -
ZIOPHARM (ZIOP) to launch Phase 1 clinical trial of off-the-shelf primary NK cells for investigational therapy of acute myeloid leukemia in 2016
Tickers: ZIOP, XON
Occurred on: Nov 06, 2017 -
ZIOPHARM (ZIOP) to launch Phase 1 study of a viral-based CAR T-cell therapy for myeloid malignancies in 2016
Tickers: ZIOP, XON
Occurred on: Jun 28, 2017 -
Use of Intrexon's (XON) OX513A Engineered Mosquitos Approved by Florida Keys Mosquito Control District to Reduce Zika Threat
Ticker: XON
Occurred on: Nov 21, 2016 -
Fibrocell and Intrexon Announce Collaboration to Address Chronic Inflammatory and Degenerative Diseases of the Joint
Tickers: FCSC, XON
Occurred on: Jan 04, 2016
Strategic Initiatives (XON)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
